The Disease Forecasting Company.
The world’s most trusted independent health intelligence, cited over 16,000 times in 2022
Analysis & Insights
Wegovy costs $1.1m to prevent one heart attack, stroke, or cardiovascular death
Airfinity analysis on data from the Wegovy trial on cardiovascular outcomes reveals that even after a 65% rebate on the list price, it will cost $1.1m to prevent one heart attack, stroke or cardiovascular death.
Read More →
More from Airfinity
Climate change and vector-borne disease outbreaks: what you need to know
‘Tripledemic’ peak in US and UK hospitalisations to be smaller than last year as new COVID waves start in both countries
Elderly RSV vaccines to generate $10.5B annually by 2030 in G7 countries
Airfinity forecasts the severely obese population with metabolic syndrome in the US to grow 50% by 2030 from 26 million to 39.1 million people.
How a little-known London start-up predicted China’s deadly Covid outbreak
View All →
In the News
El Niño and a hotter, wetter climate aid spread of disease
Financial Times | Sep 14, 2023
FDA Approves Updated Covid Vaccines From Pfizer and Moderna
Bloomberg | Sep 11, 2023
Worth the weight: Wegovy fattens up Novo’s valuation
The Times | Sep 9, 2023
COVID-19 on the rise in Europe as bloc flies blind into fall and winter
Politico | Sep 7, 2023
View All →
A pioneer in predictive health intelligence
Understand
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Predict
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Act
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
The world's most comprehensive infectious disease solutions.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.
OUR PLATFORM:
New science
Market & Production
Policies
Disease & Prevalence
What our users say?
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
Director General,
IFPMA
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,
The Economist